To compare which is more useful in treatment of acute bronchiolitis with N-Acetyl Cysteine vs 3% NaCl

Effectiveness of N-Acetyl Cysteine vs 3% NaCl nebulisation in children with acute bronchiolitis aged 6 months to 2 years: A randomized controlled trial - Nil

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/10/096708

Enrollment

Registered

2025-10-31

Start date

Unknown

Completion date

Unknown

Last updated

2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J219- Acute bronchiolitis, unspecified

Interventions

Intervention1: N-acetyl cysteine: N-acetyl cysteine of dose 20mg is used in the form of nebulization 3 times a day then reduce the frequency of nebulization based on the improvement of the symptoms fo

Eligibility

Inclusion criteria

Inclusion criteria: First episode of respiratory distress associated with wheezing Clinical severity score more than 3 No evidence of bacterial infection

Exclusion criteria

Exclusion criteria: Cardiac diseases such as congenital heart disease Preterm birth or history of mechanical ventilation in neonatal period History of pneumonia

Design outcomes

Primary

Measure	Time frame
To evaluate the mean duration of hospital stay and change in clinical severity score parameters (respiratory rate ,o2 saturation,wheezing,retraction,general condition )Timepoint: Assess pre treatment severity before 1st nebulization Detect early response after 1st dose(after 6 hours of 1st dose),Evaluate ongoing improvement(on day 2,3,4) and final clinal outcome based on reduction of clinical severity score (on day 5)	—

Measure

Time frame

To evaluate the mean duration of hospital stay and change in clinical severity score parameters (respiratory rate ,o2 saturation,wheezing,retraction,general condition )Timepoint: Assess pre treatment severity before 1st nebulization Detect early response after 1st dose(after 6 hours of 1st dose),Evaluate ongoing improvement(on day 2,3,4) and final clinal outcome based on reduction of clinical severity score (on day 5)

—

Secondary

Measure	Time frame
NilTimepoint: Nil	—

Countries

India

Contacts

Public ContactDr Thiyagaraajan

Aarupadai veedu medical college and hospital

chandru14885@gmail.com9791783036

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026